Vulnerable COPD patients with comorbidities: The role of rofumilast

Therapeutics and Clinical Risk Management

Volumn 10, Issue , 2014, Pages 969-976

  Lipari, Melissa ^a,b   Kale Pradhan, Pramodini B ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE;

ANTIINFLAMMATORY ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ASIAN; BODY WEIGHT DISORDER; BRONCHOCONSTRICTION; CARDIOVASCULAR DISEASE; CAUCASIAN; CHILD PUGH SCORE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORTICOSTEROID INDUCED MYOPATHY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HUMAN; HYPERINFLATION; INSOMNIA; ISCHEMIC HEART DISEASE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MUSCLE WEAKNESS; NAUSEA; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT DISEASE; REVIEW; SINGLE DRUG DOSE; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SUICIDE; SUICIDE ATTEMPT; WEIGHT REDUCTION;

EID: 84919329574     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S55105     Document Type: Review

References (39)

1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease; 2014. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf. Accessed August 11, 2014.
2. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887–1894.
3. Iversen KK, Kjaergaard J, Akkan D, et al; ECHOS Lung Function Study Group. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail. 2010;12(7):685–691.
4. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16): 1810–1852.
5. Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians, et al. 2012 ACCF/AHA/ACP/ AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164.
6. Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: The McGraw-Hill Companies; 2011:277–355.
7. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566.
8. Mainguy V, Girard D, Maltais F, et al. Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. Am J Cardiol. 2012;110(2):258–263.
9. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67(11):977–984.
10. Madsen H, Brixen K, Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease – a population-based database study. Clin Respir J. 2010;4(1):22–29.
11. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343(26):1902–1909.
12. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009;136(6): 1456–1465.
13. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340(25):1948–1953.
14. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airfow obstruction. Am J Respir Crit Care Med. 1994;150(1):11–16.
15. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153(6 Pt 1):1958–1964.
16. Daliresp® (rofumilast) tablets [prescribing information]. Oranienburg: Nycomed GmbH; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022522s000lbl.pdf. Accessed August 11, 2014.
17. Rabe KF. Update on rofumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53–67.
18. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor rofumilast – the importance of defning different subsets of patients with COPD. Respir Res. 2011;12:18.
19. Hermann R, Nassr N, Lahu G, et al. Steady-state pharmacokinetics of rofumilast and rofumilast N-oxide in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet. 2007;46(5):403–416.
20. Bethke TD, Hartmann M, Hünnemeyer A, Lahu G, Gleiter CH. Infu-ence of renal impairment on the pharmacokinetics of oral rofumilast: an open-label, parallel-group, single-center study. Int J Clin Pharmacol Ther. 2011;49(8):491–499.
21. Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12(3):275–286.
22. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of rofumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235–256.
23. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor rofumilast in patients with COPD. Thorax. 2007;62(12):1081–1087.
24. Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, et al. Rofumilast attenuates pulmonary infammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2008;21(4):616–623.
25. Hauns B, Hermann R, Hünnemeyer A, et al. Investigation of a potential food effect on the pharmacokinetics of rofumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(10):1146–1153.
26. Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbröker D, Bethke TD. Rofumilast – an oral anti-infammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485):563–571.
27. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with rofumi-last in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154–161.
28. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Rofumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–694.
29. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al; M2-127 and M2-128 study groups. Rofumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting broncho-dilators: two randomised clinical trials. Lancet. 2009;374(9691): 695–703.
30. Bateman ED, Rabe KF, Calverley PM, et al. Rofumilast with long-acting β2-agonists for COPD: infuence of exacerbation history. Eur Respir J. 2011;38(3):553–560.
31. Lee SD, Hui DS, Mahayiddin AA, et al. Rofumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology. 2011;16(8):1249–1257.
32. Zheng J, Yang J, Zhou X, et al. Rofumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest. 2014;145(1):44–52.
33. Oba Y, Lone NA. Effcacy and safety of rofumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2013;7(1):13–24.
34. Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Does rofumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis. 2012;7:375–382.
35. Rutten-van Mölken MP, van Nooten FE, Lindemann M, Caeser M, Calverley PM. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics. 2007;25(8): 695–711.
36. Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:183–199.
37. Samyshkin Y, Kotchie RW, Mörk AC, Briggs AH, Bateman ED. Cost-effectiveness of rofumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ. 2014;15(1):69–82.
38. Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–141.
39. Red Book Online. 2013. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/redbook. ModifyRedBookSearch. Accessed August 11, 2014.